Marianne M. Stanford

发表

Intravenously Administered Alphavirus Vector VA7 Eradicates Orthotopic Human Glioma Xenografts in Nude Mice

M. Vähä-Koskela, J. Bell, J. A. McCart, 2010, PloS one.

Combination of poly I:C and Pam3CSK4 enhances activation of B cells in vitro and boosts antibody responses to protein vaccines in vivo

D. Hoskin, M. Stanford, M. Mansour, 2017, PloS one.

Using MRI cell tracking to monitor immune cell recruitment in response to a peptide‐based cancer vaccine

C. Bowen, M. Stanford, K. Brewer, 2017, Magnetic resonance in medicine.

Novel Peptide-Based PD1 Immunomodulators Demonstrate Efficacy in Infectious Disease Vaccines and Therapeutics

James Pannucci, V. Kotraiah, M. Tsuji, 2020, Frontiers in Immunology.

Immunopathogenesis of poxvirus infections: forecasting the impending storm

G. McFadden, G. Karupiah, G. Chaudhri, 2007, Immunology and cell biology.

Myxoma virus and oncolytic virotherapy: a new biologic weapon in the war against cancer

G. McFadden, M. Stanford, Marianne M. Stanford, 2007, Expert opinion on biological therapy.

Using lymph node swelling as a potential biomarker for successful vaccination

C. Bowen, M. Stanford, M. Mansour, 2016, Oncotarget.

Using MRI to evaluate and predict therapeutic success from depot-based cancer vaccines

C. Bowen, M. Stanford, M. Mansour, 2015, Molecular therapy. Methods & clinical development.

A Respiratory Syncytial Virus Vaccine Based on the Small Hydrophobic Protein Ectodomain Presented With a Novel Lipid-Based Formulation Is Highly Immunogenic and Safe in Adults: A First-in-Humans Study

J. Langley, B. Schepens, X. Saelens, 2018, The Journal of infectious diseases.

Survivin-targeted immunotherapy drives robust polyfunctional T cell generation and differentiation in advanced ovarian cancer patients

M. Buyse, A. Oza, J. Nemunaitis, 2015, Oncoimmunology.

Infection of human cancer cells with myxoma virus requires Akt activation via interaction with a viral ankyrin-repeat host range factor.

J. Cheng, G. McFadden, Mei Sun, 2006, Proceedings of the National Academy of Sciences of the United States of America.

Myxoma virus in the European rabbit: interactions between the virus and its susceptible host.

G. McFadden, M. Stanford, Marianne M. Stanford, 2007, Veterinary research.

M-T5, the Ankyrin Repeat, Host Range Protein of Myxoma Virus, Activates Akt and Can Be Functionally Replaced by Cellular PIKE-A

G. McFadden, J. Barrett, M. Stanford, 2006, Journal of Virology.

The 'supervirus'? Lessons from IL-4-expressing poxviruses.

G. McFadden, M. Stanford, Marianne M. Stanford, 2005, Trends in immunology.

First-in-man application of a novel therapeutic cancer vaccine formulation with the capacity to induce multi-functional T cell responses in ovarian, breast and prostate cancer patients

J. Nemunaitis, K. Odunsi, M. Morse, 2012, Journal of Translational Medicine.

Generation of highly activated, antigen-specific tumor-infiltrating CD8+ T cells induced by a novel T cell-targeted immunotherapy

M. Stanford, Marianne M. Stanford, L. Portales-Cervantes, 2020, Oncoimmunology.

The relative activity of CXCR3 and CCR5 ligands in T lymphocyte migration: concordant and disparate activities in vitro and in vivo

M. Stanford, T. Issekutz, Marianne M. Stanford, 2003, Journal of leukocyte biology.

Targeting tumor vasculature with an oncolytic virus.

H. Atkins, A. Fenster, D. Kirn, 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

Identification of host range mutants of myxoma virus with altered oncolytic potential in human glioma cells

G. McFadden, J. Barrett, Fuan Wang, 2007, Journal of NeuroVirology.

Enhancement of Vaccinia Virus Based Oncolysis with Histone Deacetylase Inhibitors

H. Atkins, J. Diallo, D. Kirn, 2010, PloS one.

Targeting human medulloblastoma: oncolytic virotherapy with myxoma virus is enhanced by rapamycin.

T. Alain, G. McFadden, Beicheng Sun, 2007, Cancer research.

Myxoma virus oncolysis of primary and metastatic B16F10 mouse tumors in vivo.

G. McFadden, A. Chambers, J. Barrett, 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

Combination of a T cell activating therapy and anti-phosphatidylserine enhances anti-tumour immune responses in a HPV16 E7-expressing C3 tumour model

Brennan S. Dirk, M. Stanford, O. Hrytsenko, 2021, Scientific Reports.

Delineation of Five Thyroglobulin T Cell Epitopes with Pathogenic Potential in Experimental Autoimmune Thyroiditis1

M. Stanford, P. Verginis, Marianne M. Stanford, 2002, The Journal of Immunology.

Unique depot formed by an oil based vaccine facilitates active antigen uptake and provides effective tumour control

C. Bowen, M. Stanford, Iulia Dude, 2018, Journal of Biomedical Science.

Potent oncolytic activity of raccoonpox virus in the absence of natural pathogenicity.

J. Barrett, M. Vähä-Koskela, J. Bell, 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

RH5.1-CyRPA-Ripr antigen combination vaccine shows little improvement over RH5.1 in a preclinical setting

A. Cowman, V. Kotraiah, J. Healer, 2022, Frontiers in Cellular and Infection Microbiology.

Oncolytic Virotherapy Synergism with Signaling Inhibitors: Rapamycin Increases Myxoma Virus Tropism for Human Tumor Cells

G. McFadden, J. Barrett, M. Stanford, 2006, Journal of Virology.

Metronomic cyclophosphamide enhances HPV16E7 peptide vaccine induced antigen-specific and cytotoxic T-cell mediated antitumor immune response

M. Stanford, M. Mansour, N. Berinstein, 2014, Oncoimmunology.

First-inman application of a novel therapeutic cancer vaccine formulation with the capacity to induce multi-functional T cell responses in ovarian , breast and prostate cancer patients

J. Nemunaitis, K. Odunsi, M. Morse, 2012 .